Mineralys Therapeutics, Inc. MLYS
We take great care to ensure that the data presented and summarized in this overview for Mineralys Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in MLYS
Top Purchases
Top Sells
About MLYS
Insider Transactions at MLYS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 11
2024
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,026
-3.44%
|
$75,390
$15.0 P/Share
|
|
Nov 11
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,043
+3.38%
|
$0
$0.81 P/Share
|
|
Nov 06
2024
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
25,482
-15.78%
|
$382,230
$15.03 P/Share
|
|
Nov 06
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,482
+13.63%
|
$25,482
$1.08 P/Share
|
|
Oct 14
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,352
+3.79%
|
$5,352
$1.08 P/Share
|
|
Oct 11
2024
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,271
-1.68%
|
$198,523
$13.52 P/Share
|
|
Oct 11
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,017
+3.7%
|
$0
$0.54 P/Share
|
|
Oct 11
2024
|
Adam Scott Levy CFO and Secretary |
SELL
Open market or private sale
|
Direct |
10,757
-4.34%
|
$139,841
$13.57 P/Share
|
|
Sep 12
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,349
+4.81%
|
$6,349
$1.08 P/Share
|
|
Sep 11
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,018
+4.04%
|
$0
$0.54 P/Share
|
|
Aug 12
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,365
+4.85%
|
$0
$0.81 P/Share
|
|
Jul 24
2024
|
Brian Taylor Slingsby Director |
SELL
Open market or private sale
|
Indirect |
550,000
-5.98%
|
$7,150,000
$13.05 P/Share
|
|
Jul 16
2024
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
525
-0.51%
|
$7,875
$15.0 P/Share
|
|
Jul 16
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
525
+0.51%
|
$525
$1.08 P/Share
|
|
Jul 12
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,349
+5.81%
|
$6,349
$1.08 P/Share
|
|
Jul 11
2024
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,746
-1.7%
|
$204,698
$13.34 P/Share
|
|
Jul 11
2024
|
Adam Scott Levy CFO and Secretary |
SELL
Open market or private sale
|
Direct |
10,757
-4.16%
|
$139,841
$13.14 P/Share
|
|
Jul 11
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,017
+4.94%
|
$0
$0.54 P/Share
|
|
Jun 20
2024
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
14,940
-1.59%
|
$164,340
$11.73 P/Share
|
|
Jun 18
2024
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
16,607
-1.73%
|
$182,677
$11.99 P/Share
|
Last 12 Months Summary
Buy / Acquisition
2.94M
Shares
From
5
Insiders
| Grant, award, or other acquisition | 2.23M shares |
|---|---|
| Open market or private purchase | 560K shares |
| Exercise of conversion of derivative security | 154K shares |
Sell / Disposition
853K
Shares
From
4
Insiders
| Open market or private sale | 853K shares |
|---|